HC Wainwright Has Positive Estimate for ACHV FY2026 Earnings

Achieve Life Sciences, Inc. (NASDAQ:ACHV) – Equities researchers at HC Wainwright boosted their FY2026 earnings estimates for shares of Achieve Life Sciences in a research report issued on Wednesday, March 25th. HC Wainwright analyst B. Folkes now expects that the biopharmaceutical company will earn ($1.28) per share for the year, up from their prior estimate of ($1.35). HC Wainwright has a “Buy” rating and a $12.00 price target on the stock. The consensus estimate for Achieve Life Sciences’ current full-year earnings is ($1.17) per share. HC Wainwright also issued estimates for Achieve Life Sciences’ FY2027 earnings at ($1.24) EPS, FY2028 earnings at $0.36 EPS, FY2029 earnings at $1.52 EPS and FY2030 earnings at $2.31 EPS.

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Achieve Life Sciences in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $15.50.

Achieve Life Sciences Price Performance

ACHV stock opened at $2.89 on Friday. The company has a debt-to-equity ratio of 0.52, a quick ratio of 5.14 and a current ratio of 4.39. Achieve Life Sciences has a 1 year low of $1.84 and a 1 year high of $6.03. The firm has a market cap of $153.83 million, a P/E ratio of -2.22 and a beta of 1.81. The stock has a 50-day simple moving average of $4.38 and a 200-day simple moving average of $4.29.

Achieve Life Sciences (NASDAQ:ACHV) last released its quarterly earnings data on Tuesday, March 24th. The biopharmaceutical company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.01).

Institutional Trading of Achieve Life Sciences

A number of hedge funds and other institutional investors have recently modified their holdings of ACHV. Franklin Resources Inc. lifted its stake in shares of Achieve Life Sciences by 81.3% in the second quarter. Franklin Resources Inc. now owns 4,459,014 shares of the biopharmaceutical company’s stock worth $10,077,000 after acquiring an additional 2,000,079 shares in the last quarter. Vanguard Group Inc. increased its holdings in Achieve Life Sciences by 14.5% during the 3rd quarter. Vanguard Group Inc. now owns 2,461,802 shares of the biopharmaceutical company’s stock worth $7,755,000 after purchasing an additional 311,925 shares during the last quarter. Millennium Management LLC increased its holdings in Achieve Life Sciences by 472.3% during the 4th quarter. Millennium Management LLC now owns 1,359,116 shares of the biopharmaceutical company’s stock worth $6,755,000 after purchasing an additional 1,121,614 shares during the last quarter. Hudson Bay Capital Management LP acquired a new position in shares of Achieve Life Sciences in the 2nd quarter valued at approximately $2,652,000. Finally, Marshall Wace LLP boosted its stake in shares of Achieve Life Sciences by 31.5% during the 4th quarter. Marshall Wace LLP now owns 1,019,281 shares of the biopharmaceutical company’s stock valued at $5,066,000 after buying an additional 244,428 shares during the last quarter. 33.52% of the stock is owned by hedge funds and other institutional investors.

Achieve Life Sciences News Roundup

Here are the key news stories impacting Achieve Life Sciences this week:

• Positive Sentiment: HC Wainwright reaffirmed a “Buy” rating and set a $12 price target, raising visibility on upside if cytisinicline gains FDA approval and commercial traction; the firm also published short‑term EPS forecasts tied to ongoing development. HC Wainwright Buy Rating
• Positive Sentiment: Unusually large retail/institutional call option purchases were reported, signaling speculative bullish positioning that can amplify near‑term upside and volatility. Investors Purchase Call Options
• Positive Sentiment: Publication in Nicotine & Tobacco Research linked cytisinicline’s receptor selectivity to low nausea and favorable tolerability — data that supports the drug’s safety profile and could aid regulatory review and prescriber adoption. GlobeNewswire Publication
• Positive Sentiment: Analyst/industry commentary highlights an upcoming FDA PDUFA date (June 20, 2026) for cytisinicline and plans to start a Phase 3 vaping‑cessation trial (ORCA‑V2) in 1H 2026 — both are key milestones that could create major value inflection points if positive. Seeking Alpha PDUFA / Vaping Expansion
• Neutral Sentiment: Company Q4 2025 earnings call and accompanying summaries reviewed program timelines, manufacturing partnerships and commercialization planning — useful for modeling but no new regulatory decision was announced on the call. Q4 2025 Earnings Call Summary
• Negative Sentiment: Q4 2025 results showed a slight EPS miss (reported -$0.28 vs. consensus -$0.27) and the company remains unprofitable with negative forward EPS consensus; until regulatory approval and commercial revenue arrive, cash burn and dilution risk remain headwinds. Q4 2025 Earnings Call Transcript

About Achieve Life Sciences

Achieve Life Sciences, Inc (NASDAQ: ACHV) is a clinical-stage biotechnology company dedicated to the development and commercialization of cytisinicline, a plant-derived alkaloid for smoking cessation. The company’s mission is to offer a novel, evidence-based therapy that addresses the global need for effective and well-tolerated smoking cessation options. Achieve focuses its efforts on advancing the clinical profile of cytisinicline through rigorous development programs and regulatory engagement.

Cytisinicline (formerly marketed as Tabex® in Europe) acts as a nicotinic acetylcholine receptor partial agonist, helping reduce withdrawal symptoms and nicotine cravings.